Novo Nordisk As Stock Shares Outstanding
| NVO Stock | USD 122.71 0.04 0.03% |
Novo Nordisk AS fundamentals help investors to digest information that contributes to Novo Nordisk's financial success or failures. It also enables traders to predict the movement of Novo Stock. The fundamental analysis module provides a way to measure Novo Nordisk's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Novo Nordisk stock.
As of the 19th of April 2024, Common Stock Shares Outstanding is likely to drop to about 4 B. Novo | Shares Outstanding |
Novo Nordisk AS Company Shares Outstanding Analysis
Novo Nordisk's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Novo Nordisk Shares Outstanding | 4.46 B |
Most of Novo Nordisk's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Novo Nordisk AS is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Novo Shares Outstanding Driver Correlations
Understanding the fundamental principles of building solid financial models for Novo Nordisk is extremely important. It helps to project a fair market value of Novo Stock properly, considering its historical fundamentals such as Shares Outstanding. Since Novo Nordisk's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Novo Nordisk's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Novo Nordisk's interrelated accounts and indicators.
Click cells to compare fundamentals
Novo Shares Outstanding Historical Pattern
Today, most investors in Novo Nordisk Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Novo Nordisk's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's shares outstanding growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Novo Nordisk shares outstanding as a starting point in their analysis.
Novo Nordisk Shares Outstanding |
| Timeline |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Novo Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
Based on the latest financial disclosure, Novo Nordisk AS has 4.46 B of shares currently outstending. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The shares outstanding for all United States stocks is significantly lower than that of the firm.
Novo Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Novo Nordisk's direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Novo Nordisk could also be used in its relative valuation, which is a method of valuing Novo Nordisk by comparing valuation metrics of similar companies.Novo Nordisk is currently under evaluation in shares outstanding category among related companies.
Novo Nordisk Current Valuation Drivers
We derive many important indicators used in calculating different scores of Novo Nordisk from analyzing Novo Nordisk's financial statements. These drivers represent accounts that assess Novo Nordisk's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Novo Nordisk's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 727.7B | 916.6B | 986.1B | 2.1T | 3.1T | 3.3T | |
| Enterprise Value | 712.6B | 905.6B | 983.7B | 2.1T | 3.1T | 3.3T |
Novo Fundamentals
| Return On Equity | 0.88 | ||||
| Return On Asset | 0.23 | ||||
| Profit Margin | 0.36 % | ||||
| Operating Margin | 0.43 % | ||||
| Current Valuation | 551.97 B | ||||
| Shares Outstanding | 4.46 B | ||||
| Shares Owned By Institutions | 9.28 % | ||||
| Number Of Shares Shorted | 2.83 M | ||||
| Price To Earning | 37.42 X | ||||
| Price To Book | 36.21 X | ||||
| Price To Sales | 2.43 X | ||||
| Revenue | 232.26 B | ||||
| Gross Profit | 148.51 B | ||||
| EBITDA | 112.94 B | ||||
| Net Income | 83.68 B | ||||
| Cash And Equivalents | 37.47 B | ||||
| Cash Per Share | 16.57 X | ||||
| Total Debt | 27.01 B | ||||
| Debt To Equity | 0.34 % | ||||
| Current Ratio | 0.92 X | ||||
| Book Value Per Share | 23.90 X | ||||
| Cash Flow From Operations | 108.91 B | ||||
| Short Ratio | 0.50 X | ||||
| Earnings Per Share | 2.65 X | ||||
| Price To Earnings To Growth | 2.40 X | ||||
| Target Price | 143.37 | ||||
| Number Of Employees | 63.37 K | ||||
| Beta | 0.2 | ||||
| Market Capitalization | 547.39 B | ||||
| Total Asset | 314.49 B | ||||
| Retained Earnings | 104.84 B | ||||
| Working Capital | (30.01 B) | ||||
| Current Asset | 8.03 B | ||||
| Current Liabilities | 5.95 B | ||||
| Annual Yield | 0.01 % | ||||
| Five Year Return | 2.05 % | ||||
| Net Asset | 314.49 B | ||||
| Last Dividend Paid | 9.4 |
About Novo Nordisk Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Novo Nordisk AS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Novo Nordisk using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Novo Nordisk AS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Novo Nordisk Investors Sentiment
The influence of Novo Nordisk's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Novo. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Novo Nordisk's public news can be used to forecast risks associated with an investment in Novo. The trend in average sentiment can be used to explain how an investor holding Novo can time the market purely based on public headlines and social activities around Novo Nordisk AS. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Novo Nordisk's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Novo Nordisk's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Novo Nordisk's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Novo Nordisk.
Novo Nordisk Implied Volatility | 38.63 |
Novo Nordisk's implied volatility exposes the market's sentiment of Novo Nordisk AS stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Novo Nordisk's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Novo Nordisk stock will not fluctuate a lot when Novo Nordisk's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Novo Nordisk in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Novo Nordisk's short interest history, or implied volatility extrapolated from Novo Nordisk options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Novo Nordisk Piotroski F Score and Novo Nordisk Altman Z Score analysis. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Complementary Tools for Novo Stock analysis
When running Novo Nordisk's price analysis, check to measure Novo Nordisk's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novo Nordisk is operating at the current time. Most of Novo Nordisk's value examination focuses on studying past and present price action to predict the probability of Novo Nordisk's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novo Nordisk's price. Additionally, you may evaluate how the addition of Novo Nordisk to your portfolios can decrease your overall portfolio volatility.
| CEOs Directory Screen CEOs from public companies around the world | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |
Is Novo Nordisk's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novo Nordisk. If investors know Novo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novo Nordisk listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.631 | Dividend Share 9.4 | Earnings Share 2.65 | Revenue Per Share 51.812 | Quarterly Revenue Growth 0.37 |
The market value of Novo Nordisk AS is measured differently than its book value, which is the value of Novo that is recorded on the company's balance sheet. Investors also form their own opinion of Novo Nordisk's value that differs from its market value or its book value, called intrinsic value, which is Novo Nordisk's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novo Nordisk's market value can be influenced by many factors that don't directly affect Novo Nordisk's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novo Nordisk's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novo Nordisk is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novo Nordisk's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.